INTEGRATE: Regorafenib in refractory advanced oesophagogastric cancer

Speaker: Michel Ducreux

M. Ducreux reviews current standard of treatment for advanced oesophagogastric cancer. He says that a rationale for studying regorafenib in refractory oesophagogastric cancer is same as in refractory metastatic colorectal cancer because of drug’s Antiangiogenic and multitargeting properties and altered tumour biology in advance disease setting. He elaborates results from a randomised phase II study of regorafenib vs placebo in refractory oesophagogastric cancer.

Discussion Points

  • Where are we today in the managment of advanced oesophagogastric cancer?
  • What is a rationale for studying regorafenib in the refractory setting?
  • The results of the AGITG randomised phase II study of regorafenib vs placebo in refractory oesophagogastric cancer